Because hypoxia is a common feature of the bone marrow microenvironment that promotes HIF-dependent blood cancer progression and resistance to therapy47, our data call for evaluation of hypoxia-regulated CSRP2 expression in blood cancers. The gene discussed is CSRP2; the disease is hematopoietic and lymphoid system neoplasm.